Marshall Wace’s Nautilus Biotechnolgy NAUT Stock Holding History

Marshall Wace’s Portfolio NAUT Stock Details NAUT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$497K	Sell	265,582 -54,300	-17%	-$143K	﹤0.01%	2525
2026 Q1	$1.24M	Buy	319,882 +202,823	+173%	+$498K	﹤0.01%	2029
2025 Q4	$228K	Buy	+117,059	New	+$192K	﹤0.01%	2554
2022 Q3	–	Sell	-11,500	Closed	-$30K	–	3647
2022 Q2	$30K	Buy	+11,500	New	+$42.8K	﹤0.01%	3349
2022 Q1	–	Sell	-37,713	Closed	-$195K	–	3772
2021 Q4	$195K	Sell	37,713 -128,613	-77%	-$688K	﹤0.01%	3164
2021 Q3	$1.02M	Buy	166,326 +99,128	+148%	+$790K	﹤0.01%	2002
2021 Q2	$679K	Buy	+67,198	New	+$728K	﹤0.01%	1987

Other funds holding NAUT

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACM

AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CFM

Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Marshall Wace's NAUT Position: Q2 2026 in Review

Marshall Wace reduced its Nautilus Biotechnolgy (NAUT) stake by 17% in Q2 2026, selling an estimated $143K and leaving 265,582 shares worth $497K. The position accounts for ﹤0.01% of the portfolio, ranked #2525.

Marshall Wace first reported a position in NAUT in Q2 2021 and has held it in 7 quarters since. The position peaked at $1.24M in Q1 2026. 93 funds tracked by Wall St. Rank hold NAUT as of Q2 2026.

Marshall Wace held 265,582 shares of Nautilus Biotechnolgy worth $497K as of Q2 2026.
Marshall Wace sold 54,300 Nautilus Biotechnolgy shares in Q2 2026, an estimated $143K.
Nautilus Biotechnolgy made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2525 holding.
Marshall Wace first reported a position in Nautilus Biotechnolgy in Q2 2021 and has held it in 7 quarters since.
Marshall Wace's Nautilus Biotechnolgy position peaked at $1.24M in Q1 2026.
93 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.